V114 15价肺炎球菌结合疫苗在≥50岁健康成人中的安全性、耐受性和免疫原性:一项随机III期试验
这项III期试验将652名≥50岁健康成人按1:1随机分配,分别接种V114或PCV13,12个月后接种PPSV23。结果显示V114序贯PPSV23耐受性良好,对15种血清型诱导的抗体水平与PCV13序贯PPSV23相当,且对V114独有血清型22F和33F的免疫应答更高。
要点
- V114序贯PPSV23在≥50岁健康成人中安全性良好,严重不良事件发生率低且与研究疫苗无关。
- 接种PPSV23后,V114组对全部15种血清型的免疫应答与PCV13组相当。
- V114对独有血清型22F和33F的免疫应答高于PCV13组。
核心结论
- V114序贯PPSV23在≥50岁健康成人中耐受性良好,诱导的抗体水平与PCV13序贯PPSV23相当。
研究设计与样本
- III期随机试验(NCT03480763),652名≥50岁健康成人按1:1随机接种V114或PCV13,12个月后接种PPSV23。
主要发现
- PCV接种后最常见征集性不良事件为注射部位疼痛和疲劳,V114组发生率较高但无临床意义。
- PPSV23接种后最常见征集性不良事件为注射部位疼痛和肿胀,两组发生率相当。
- 两组严重不良事件发生率均低,且无一与研究疫苗相关;研究期间无死亡发生。
- 接种PPSV23后,V114组对全部15种血清型的血清调理吞噬活性几何平均滴度和免疫球蛋白G几何平均浓度与PCV13组相当。
- V114诱导的免疫应答持续至少12个月;接种PCV后30天和12个月时,13种共享血清型的免疫应答两组相当,V114独有血清型(22F和33F)在V114组更高。
临床怎么用
- 对于≥50岁健康成人,V114序贯PPSV23可作为PCV13序贯PPSV23的替代方案,提供对15种血清型的免疫保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Streptococcus pneumoniae causes pneumococcal disease, and older adults are at an increased risk. Sequential vaccination of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for broad protection against pneumococcal disease in some countries. METHODS: This phase III trial evaluated the safety, tolerability, and immunogenicity of sequential administration of either V114 (a 15-valent PCV containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) or PCV13, followed 12 months later by PPSV23, in healthy adults aged ≥50 years (NCT03480763). A total of 652 participants were randomized 1:1 to receive either V114 or PCV13, followed by PPSV23. RESULTS: The most common solicited adverse events (AEs) following PCV vaccination included injection-site pain and fatigue. Higher proportions of participants with these events were observed in the V114 group following PCV; however, these differences were not clinically significant. Following PPSV23 vaccination, the most common solicited AEs were injection-site pain and injection-site swelling; the proportions of participants with these events were comparable between both groups. Incidence of serious AEs was low in both groups following PCV and PPSV23, and none were related to study vaccines. No deaths occurred during the study. Serum opsonophagocytic activity geometric mean titers and immunoglobulin G geometric mean concentrations were comparable between both groups for all 15 serotypes in V114 following PPSV23. Immune responses elicited by V114 persisted for at least 12 months. Immune responses at 30 days and 12 months post-vaccination with PCV were comparable between both groups for the 13 shared serotypes and higher in the V114 group for the V114-unique serotypes (22F and 33F). CONCLUSION: Administration of V114 followed by PPSV23 was well tolerated and induced comparable antibody levels to PCV13 followed by PPSV23 in healthy adults aged ≥50 years.
引用
- Song JY, Chang CJ, Andrews C, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). Vaccine. 2021. PMID: 34489128. doi:10.1016/j.vaccine.2021.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。